Short Interest in Verastem Inc (VSTM) Expands By 13.1%

Verastem Inc (NASDAQ:VSTM) was the target of a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 18,654,118 shares, an increase of 13.1% from the October 15th total of 16,498,651 shares. Based on an average daily trading volume, of 2,428,622 shares, the short-interest ratio is currently 7.7 days. Currently, 26.0% of the company’s shares are short sold.

NASDAQ:VSTM opened at $5.51 on Friday. The company has a quick ratio of 7.70, a current ratio of 7.70 and a debt-to-equity ratio of 0.19. The stock has a market cap of $374.58 million, a PE ratio of -3.13 and a beta of 3.14. Verastem has a one year low of $2.77 and a one year high of $10.35.

Verastem (NASDAQ:VSTM) last posted its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.14. The business had revenue of $15.51 million for the quarter. On average, equities analysts predict that Verastem will post -1.64 earnings per share for the current fiscal year.

In related news, CEO Robert Forrester purchased 10,500 shares of the firm’s stock in a transaction on Thursday, September 27th. The stock was purchased at an average cost of $7.00 per share, with a total value of $73,500.00. Following the completion of the purchase, the chief executive officer now owns 209,234 shares in the company, valued at approximately $1,464,638. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Michael Kauffman purchased 4,000 shares of the firm’s stock in a transaction on Friday, September 28th. The stock was bought at an average cost of $7.49 per share, with a total value of $29,960.00. Following the completion of the purchase, the director now owns 4,000 shares of the company’s stock, valued at approximately $29,960. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 19,500 shares of company stock worth $139,420. 6.51% of the stock is owned by company insiders.

Several large investors have recently bought and sold shares of the company. Wells Fargo & Company MN increased its position in shares of Verastem by 7.9% during the third quarter. Wells Fargo & Company MN now owns 139,162 shares of the biopharmaceutical company’s stock worth $1,010,000 after acquiring an additional 10,157 shares in the last quarter. American International Group Inc. increased its position in shares of Verastem by 32.4% during the third quarter. American International Group Inc. now owns 45,584 shares of the biopharmaceutical company’s stock worth $330,000 after acquiring an additional 11,151 shares in the last quarter. Creative Planning increased its position in shares of Verastem by 30.1% during the second quarter. Creative Planning now owns 58,550 shares of the biopharmaceutical company’s stock worth $403,000 after acquiring an additional 13,550 shares in the last quarter. State Board of Administration of Florida Retirement System bought a new stake in shares of Verastem during the second quarter worth about $100,000. Finally, Metropolitan Life Insurance Co. NY bought a new stake in shares of Verastem during the second quarter worth about $130,000. 43.40% of the stock is owned by institutional investors.

Several research firms have weighed in on VSTM. ValuEngine raised shares of Verastem from a “buy” rating to a “strong-buy” rating in a research note on Wednesday. HC Wainwright set a $15.00 price target on shares of Verastem and gave the company a “buy” rating in a research note on Thursday. BidaskClub downgraded shares of Verastem from a “buy” rating to a “hold” rating in a research note on Friday, October 26th. Zacks Investment Research raised shares of Verastem from a “hold” rating to a “buy” rating and set a $9.00 price target for the company in a research note on Friday, July 20th. Finally, Raymond James lifted their price target on shares of Verastem from $7.00 to $12.00 in a research note on Friday, August 10th. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $14.60.

TRADEMARK VIOLATION NOTICE: “Short Interest in Verastem Inc (VSTM) Expands By 13.1%” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international copyright and trademark laws. The correct version of this report can be viewed at https://www.americanbankingnews.com/2018/11/10/short-interest-in-verastem-inc-vstm-expands-by-13-1.html.

Verastem Company Profile

Verastem, Inc, a biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K) signaling pathways. The company's lead FAK inhibitor is defactinib, an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds.

Featured Article: NASDAQ

Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply